哌拉西林-他唑巴坦与碳青霉烯类治疗后的碳青霉烯耐药肠杆菌目获得风险:倾向匹配队列研究
这项在以色列单中心开展的回顾性倾向匹配队列研究纳入2014至2023年接受哌拉西林-他唑巴坦(PTZ)或碳青霉烯类治疗至少5天的成人患者,比较两组在治疗开始后第5至90天获得碳青霉烯耐药肠杆菌目(CRE)的风险。全队列中PTZ组CRE获得率为4.5%(219/4887),碳青霉烯组为9.3%(264/2844),未调整OR 0.46(95%CI 0.38-0.55);倾向匹配队列中分别为6.4%(130/2018)与8.7%(175/2018),匹配OR 0.72(95%CI 0.57-0.92)。在CRE流行地区,碳青霉烯类治疗与PTZ相比与CRE获得显著相关。
要点
- 全队列CRE获得率:PTZ组4.5%(219/4887)vs 碳青霉烯组9.3%(264/2844),未调整OR 0.46(95%CI 0.38-0.55)。
- 倾向匹配队列CRE获得率:PTZ组6.4%(130/2018)vs 碳青霉烯组8.7%(175/2018),匹配OR 0.72(95%CI 0.57-0.92)。
- 独立危险因素包括血液肿瘤或神经外科病房住院、较长抗生素暴露和住院时间、血流感染、低白蛋白及较高血糖水平。
核心结论
- 在CRE流行地区,与PTZ相比,碳青霉烯类治疗与CRE获得显著相关。
研究设计与样本
- 回顾性队列研究,采用倾向评分匹配,在以色列一家大型医院2014至2023年开展。
- 纳入所有接受PTZ或碳青霉烯类治疗至少5天的成人患者,排除治疗开始时已知CRE携带者及PTZ组在PTZ开始前30天内或开始后90天内接受碳青霉烯类的患者。
- 共纳入7731例患者;采用1:1最近邻匹配,卡钳值0.01;另对全队列进行逆概率治疗加权回归模型的敏感性分析。
主要发现
- 全队列中6.2%(483/7731)获得CRE:PTZ组4.5%(219/4887)vs 碳青霉烯组9.3%(264/2844),未调整OR 0.46(95%CI 0.38-0.55)。
- 匹配队列中CRE获得:PTZ组6.4%(130/2018)vs 碳青霉烯组8.7%(175/2018),倾向评分匹配OR 0.72(95%CI 0.57-0.92)。
- 独立危险因素包括血液肿瘤或神经外科病房住院、较长抗生素暴露和住院时间、血流感染、低白蛋白及较高血糖水平。
- 经上述因素调整及逆概率治疗加权后,PTZ与CRE获得的OR为0.81(95%CI 0.66-0.98)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to quantify the ecological consequences of carbapenems versus piperacillin-tazobactam treatment on the risk of carbapenem-resistant Enterobacterales (CRE) acquisition. METHODS: We conducted a retrospective cohort study with propensity-score matching. The study was conducted in a single large hospital in Israel from 2014 to 2023. We included all adult patients treated with piperacillin-tazobactam (PTZ) or a carbapenem for at least 5 days. We excluded patients with known carriage of CRE at treatment initiation and patients in the PTZ group who received a carbapenem within 30 days before or 90 days after the start of PTZ. The outcome assessed was CRE acquisition through surveillance or clinical samples from day 5 to day 90 after treatment initiation. The propensity score for treatment selection was derived to match patients in the treatment groups using 1:1 nearest-neighbour matching with a calliper of 0.01. A sensitivity analysis of the full cohort was performed through a regression model of CRE acquisition, adjusting the analysis using inverse probability of treatment weighting. RESULTS: We included 7731 patients, of whom 6.2% (483/7731) acquired CRE: 4.5% (219/4887) of patients treated with PTZ versus 9.3% (264/2844) of patients treated with a carbapenem (unadjusted odds ratio [OR] 0.46, 95% CI, 0.38-0.55). In the matched cohort, CRE acquisition occurred in 6.4% (130/2018) of patients treated with PTZ versus 8.7% (175/2018) of patients treated with carbapenems (propensity score-matched OR 0.72.95% CI, 0.57-0.92). Independent risk factors for CRE acquisition included hospitalization in the haemao-oncology or neurosurgical wards, longer antibiotic exposure and hospitalization, bloodstream infections, low albumin and higher glucose levels. Adjusted to these and weighted by the inverse probability of treatment, PTZ was associated with CRE acquisition with an OR of 0.81, 95% CI, (0.66-0.98). DISCUSSION: Carbapenem were significantly associated with CRE acquisition compared with PTZ in a CRE endemic settings.
引用
- Dallasheh H, Paul M. Carbapenem-resistant Enterobacterales acquisition following piperacillin-tazobactam versus carbapenem treatment: a propensity-matched cohort study. Clin Microbiol Infect. 2025. PMID: 40222558. doi:10.1016/j.cmi.2025.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。